Rubella Seroprevalence in Korean Children

Journal of Korean Medical Science

Volumn 18, Issue 3, 2003, Pages 331-336

  Ki, Moran ^a   Choi, Bo Youl ^b   Kim, Myoung Hee ^a   Shin, Young Jeon ^b   Park, Taesung ^c  

^a Eulji University School of Medicine   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Child; Rubella; Seroepidemiologic Studies; Social Class

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; RUBELLA ANTIBODY; RUBELLA VACCINE;

ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH SURVEY; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; ONSET AGE; QUESTIONNAIRE; RUBELLA; SEROEPIDEMIOLOGY; SEROPREVALENCE; SOCIAL CLASS; VACCINATION;

EID: 0347064065     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2003.18.3.331     Document Type: Article

References (29)

1. Center for Disease Control and Prevention. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998; 47: 1-57.
2. Center for Disease Control and Prevention. Rubella and congenital ruella syndrome: United States, Jan 1,1991-May 7, 1994. MMWR 1994; 43: 397-401.
3. Center for Disease Control and Prevention. Rubella and congenital rubella syndrome: United States, 1994-1997. MMWR 1997; 46: 350-4.
4. Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331: 1397-402.
5. Robertson SE, Cutts FT, Samuel R, Dias-Ortega JL. Control of rubella and congenital rubella syndrome (CRS) in developing countries. Part 2: vaccination against rubella. B World Health Org 1997; 75: 69-80.
6. Ministry of Health and Welfare. Expanded Program on Immunization (EPI). The annual report of health and welfare, 2000. Available from URL: http://www.mohw.go.kr/hp/owa
7. National Institute of Health-Korea. Communicable Diseases Monthly Report. Seoul: National Institute of Health-Korea, 7, 1996.
8. Pecham C. Congenital rubella in the United Kingdom before 1970: the preventive era. Rev Infect Dis 1985; 7: S11-6.
9. Schaefer LE, Dyke JW, Meglio FD, Murray PR, Crafts W, Niles AC. Evaluation of microparticle enzyme immunoassays for immunoglobulins G and M to rubella virus and Toxoplasma gondii on the Abbott Imx automated analyzer. J Clin Microbiol 1989; 27: 2410-3.
10. Behring. Enzygnost Anti-Rubella-Virus/IgG Package Insert, 1998.
11. Skendzel LP. Rubella Immunity. Defining the level of protective antibody. Am J Clin Pathol 1996; 106: 170-4.
12. Lee IS, Kim CH, Lee SJ, Cho TH. Measurement of serum rubella antibody titers in Korean children, female adolescents, and pregnant women. Asia Oceania J Obstet Gynaecol 1992; 18: 345-53.
13. Fine PEM. Herd Immunity: History, Theory, Practice. Epidemiol Rev 1993; 15: 265-302.
14. Balfour HH Jr, Groth KE, Edelman CK. RA27/3 Rubella vaccine, a four year follow-up. Am J Dis Child 1980; 134: 350-3.
15. Asahi T, Ueda K, Hidaka Y, Miyazaki C, Tanaka Y, Nishima S. Twenty-three year follow-up study of rubella antibodies after immunization in a closed population, and serological response to revaccination. Vaccine 1997; 15: 1791-5.
16. Chu SY, Bernier RH, Stewart JA, Herrmann KL, Greenspan JR, Henderson AK, Liang AP. Rubella antibody persistence after immunization: sixteen-year follow-up in the Hawaiian Islands. JAMA 1988; 259: 3133-6.
17. O'Shea S, Best JM, Banatvala JE, Marshall WC, Dudgeon JA. Rubella vaccination: persistence of antibody for up to 16 years. Br Med J 1982; 285: 253-5.
18. Christenson B, Bottiger M. Long-term follow-up study of rubella anti-bodies in naturally immune and vaccinated young adults. Vaccine 1994; 12: 41-5.
19. Knox EG. Theoretical aspects of rubella vaccination strategies. Rev Infect Dis 1985 (Suppl 1); 7: S194-7.
20. Choi B, Shin YJ, Park HB, Yoon BJ, Hahn JS. A study on the positive rate of rubella antibody and the sero-conversion rate after rubella vaccination: students of 9 girls' high schools in Gyeonggi-do, Korea. Korean J Epidemiol 1993; 14: 173-84.
21. Park KS, Kim HS. Seroprevalence of rubella antibodies and effects of vaccination among healthy university women students in Korea. Yonsei Med J 1996; 37: 420-6.
22. Min CH, Lee JH, Cho MK. A study of immunogenicity of measles, mumps and rubella vaccine prepared from human diploid cell. J Korean Soc Microbiol 1991; 26: 487-91.
23. Horstmann DM, Liebhaber H, Le Bouvier GL, Rosenberg DA, Halstead SB. Rubella reinfection of vaccinated and naturally immune persons exposed in an epidemic. N Engl J Med 1970; 283: 771-8.
24. Ki MR, Kim MH, Choi BY, Shin YJ, Park TS. Rubella antibody loss rates in Korean children. Epidmiol Infection 2002; 129: 557-64.
25. Black FL. Measles. In: KR Evanse AS, ed. Viral infections of humans, epidemiology and control. 4 ed. New York: Plenum publishing Co, 1997.
26. Brody JA, Sever JL, Edgar A, McNew J. Measles antibody titer in multiple sclerosis patient and their siblings. Neurology 1972; 22: 492-9.
27. Ki MR, Kim MH, Shin YJ, Choi BY. MMR immunization rate and related factors. J Korean Pediatr Soc 2001; 44: 375-88.
28. Gutierrez Trujillo G, Munoz O, Tapia Conyer R, Bustamante Calvillo ME, Alvarez y Munoz MT, Guiscafre Gallardo JP, Magos C, Sepulveda J. The seroepidemiology of rubella in Mexican women; a national probability survey. Salud Pubilica Mex 1990; 32: 623-31.
29. Aksit S, Egemen A, Ozacar T, Kurugol Z, Keskinoglu P, Tasbakan M, Caglayan S. Rubella seroprevalence in an unvaccinated population in Izmir: recommendations for rubella vaccination in Turkey. Pediatr Infect Dis J 1999; 18: 577-80.